- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05947032
Supervised Endurance Training Among Pulmonary Arterial Hypertension Patients
Effects of Supervised Endurance Training Versus Home-based Exercise Plan on Functional Capacity and Fatigue Among Pulmonary Arterial Hypertension Patients
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
- Lady Reading Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with pulmonary arterial hypertension, not pregnant and tobacco free.
- Age = 21 to 82
- Patients with documented PAH diagnosed by echocardiography (enlarged RA an enlarged RV with a thick wall, septal shift by enlarged chambers of right side of heart, an elevated mPAP) or a resting mean pulmonary arterial pressure equal to 25mm Hg determined by right heart catheterization.
- Patients on stable PH therapies, sedentary, and had no pulmonary rehabilitation for 6 months prior to enrolment.
Exclusion Criteria:
- Patients will be excluded if they are not able to complete 6MWT.
- A documented pulmonary capillary wedge pressure greater then or equal to 15 mm Hg.
- Significant hepatic, renal, metabolic or mitochondrial dysfunctions; severe psychiatric disease; use of beta-adrenergic blockers or antiretroviral therapies; and any musculoskeletal or neurological condition that would limit walking or exercise performance.
- Patients with a history of heart failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supervised endurance exercise training + Patient Education
|
ENDURANCE TRAINING: Treadmill Walking: Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training Recumbent Bike: Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training + Patient Education |
|
Active Comparator: Home exercises + Patient Education
|
HOME EXERCISES: CONVENTIONAL Treatment: Walking: Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training Stair climbing: Frequency: 1 flight/ day Type: aerobic training + Patient Education |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue Severity Scale
Time Frame: 4 weeks
|
It measures the patient's perception of the influence of fatigue on physical and social functioning through patient's response to nine different question.
Scoring is based on likert scale where 1 indicates strong agreement and 7 indicates strong disagreement.
A score of 4 or greater is indicative of severe fatigue.
|
4 weeks
|
|
Human Activity Profile
Time Frame: 4 weeks
|
A questionnaire to assess the activity level of patient in rehabilitation with a total no of 94 questions I ascending order based on metabolic demands.
For each activity mentioned patient will be asked 1) if they are still doing this activity 2) have stopped doing this activity or never did this activity.
HAP generates two scores the maximum activity score MAS and adjusted activity score ASS.
Score < 53 is considered as low activity score between 54-73 stands for intermediate activity for high activity score > 74 is required respectively.
|
4 weeks
|
|
6MWT Distance
Time Frame: 4 weeks
|
Subject walks as fast as they can for 6 mins on a walking track to determine their ability to participate in physical activity.The 6 MWT is scored as the total distance covered in the 6-min duration of the test.
it will be measured in meters.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Muhammad Iqbal Tariq, PhD*, Riphah International University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REC/01603 Farheen Khan
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
-
University of Sao Paulo General HospitalRecruitingPulmonary Arterial Hypertension (PAH)Brazil
-
University Hospital, BrestNot yet recruitingPulmonary Arterial Hypertension (PAH)France
-
Shanghai Zhongshan HospitalNot yet recruitingPulmonary Arterial Hypertension (PAH)
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Regeneron PharmaceuticalsRecruitingPulmonary Arterial Hypertension (PAH)United States, United Kingdom, Latvia, South Korea
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
Clinical Trials on Supervised endurance exercise training + Patient Education
-
Ullevaal University HospitalNorwegian Foundation for Health and RehabilitationCompletedHip OsteoarthritisNorway
-
University of AlicanteActive, not recruitingBreast Cancer SurvivorsSpain
-
VA Office of Research and DevelopmentUniversity of Colorado, DenverRecruitingMusculoskeletal Diseases | Aging | OsteoporosisUnited States
-
Oslo University HospitalUnknownHip OsteoarthritisNorway
-
Molde University CollegeCompleted
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedEpilepsy, Generalized | Memory ImpairmentUnited States
-
University of ManchesterUnknownCardiovascular Diseases | Peripheral Arterial Disease
-
University of SevilleUniversity Hospital Virgen del Rocio, SevillaNot yet recruitingPhysical Activity | Exercise | Abdominal Wall Hernia | Prevention
-
Medical University of ViennaUnknownPeripheral Artery DiseaseAustria